Deng JH, Zhang YJ, Wang XP, Gao SJ Lytic replication-defective Kaposi's sarcoma-associated herpesvirus: potential role in infection and malignant transformation. J Virol. 2004 Oct;78(20):11108-20.
Pan H, Zhou F, Gao SJ Kaposi's sarcoma-associated herpesvirus induction of chromosome instability in primary human endothelial cells. Cancer Res. 2004 Jun 15;64(12):4064-8.
Pan HY, Zhang YJ, Wang XP, Deng JH, Zhou FC, Gao SJ Identification of a novel cellular transcriptional repressor interacting with the latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol. 2003 Sep;77(18):9758-68.
Wang XP, Gao SJ Auto-activation of the transforming viral interferon regulatory factor encoded by Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). J Gen Virol. 2003 Feb;84(Pt 2):329-36.
Wang XP, Zhang YJ, Deng JH, Pan HY, Zhou FC, Gao SJ Transcriptional regulation of Kaposi's sarcoma-associated herpesvirus-encoded oncogene viral interferon regulatory factor by a novel transcriptional silencer, Tis. J Biol Chem. 2002 Apr 5;277(14):12023-31. Epub 2002 Jan 30.
Zhang YJ, Deng JH, Rabkin C, Gao SJ Hot-spot variations of Kaposi's sarcoma-associated herpesvirus latent nuclear antigen and application in genotyping by PCR-RFLP. J Gen Virol. 2000 Aug;81(Pt 8):2049-58.
Zhang YJ, Pan HY, Gao SJ Reverse transcription slippage over the mRNA secondary structure of the LIP1 gene. Biotechniques. 2001 Dec;31(6):1286, 1288, 1290, passim.
Zhang YJ, Wang XP, Deng JH, Salinas RA, Oishi N, Gao SJ Suppression of oncogenic viral interferon regulatory factor (vIRF) of Kaposi's sarcoma-associated herpesvirus by ribozyme-mediated cleavage. Cancer Gene Ther. 2001 Apr;8(4):285-93.
KSHV Seroprevalence in Hospital Patients From San Antonio
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
